https://www.facebook.com/share/v/1Hb4ptLXBf
ZAS Corporation proudly participated in MOSB Congress 2025, reaffirming its commitment to advancing oncology care in Bangladesh through Celltrion’s biosimilar portfolio.
During the event, the ZAS oncology team engaged with distinguished medical professionals, exchanging knowledge and exploring the latest innovations in cancer treatment. These meaningful discussions reinforced the shared vision of making advanced therapies more accessible to patients in need.
ZAS Corporation remains dedicated to improving patient outcomes and collaborating with the medical community to shape a stronger, more progressive future for oncology care in Bangladesh.
